Subscribe

Nektar Therapeutics (NKTR)

USD67.76 +0.59 (+0.88%)
US NASDAQ S&P 500 Healthcare Biotechnology
Address 455 Mission Bay Boulevard South 94158
San Francisco, CA, US
CEO Howard W. Robin
Website nektar.com
IPO 1994-05-03
CIK 906709 ISIN US6402683063

Explore sections of this company profile

Also trades on London Stock Exchange · 0UNL.L (USD) NASDAQ Global Select · NKTR (USD)
Description

Nektar Therapeutics is a biopharmaceutical firm dedicated to the global discovery and advancement of therapies addressing significant unmet medical requirements. Central to its robust pipeline is Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist. This drug is currently in Phase 3 clinical trials for metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, head and neck squamous cell carcinoma, and adjuvant melanoma. It is also being evaluated in Phase 2 for renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; Phase 1/2A for head and neck squamous cell carcinoma; Phase 1/2 for various solid tumors; and Phase 1B for COVID-19. Additionally, Nektar is developing NKTR-358, a cytokine Treg stimulant, which is in Phase 2 trials for systemic lupus erythematosus and ulcerative colitis, and Phase 1B for atopic dermatitis and psoriasis. Their portfolio further includes NKTR-255, an IL-15 receptor agonist, undergoing Phase 1/2 trials for non-Hodgkin's lymphoma, multiple myeloma, head and neck cancer, and colorectal cancer. Another investigational compound, NKTR-262, a toll-like receptor agonist, is in Phase 1/2 trials for solid tumors. The company is also advancing several other drug candidates. Nektar Therapeutics maintains strategic collaboration agreements with a multitude of pharmaceutical entities, including Takeda Pharmaceutical Company Ltd., AstraZeneca AB, UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Bausch Health Companies Inc., Pfizer Inc., Amgen Inc., UCB Pharma (Biogen), Bristol-Myers Squibb Company, Baxalta Incorporated, Eli Lilly and Company, Merck KGaA, and SFJ Pharmaceuticals, Inc. Established in 1990, Nektar Therapeutics is headquartered in San Francisco, California.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Index membership

IndexAddedRemovedStatus
S&P 500 2018-03-19 — Active
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
USD67.76 +0.59 (+0.88%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
1.14
Float Shares
19.04M
Free Float %
93.8%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-0.37% -7.73% +1.20% +10.46% +36.00% +85.50% +712.75% +616.26% -71.84% -60.06% +39.43%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Analyst Consensus (33 ratings, all time) Buy
Price Targets & DCF
Current price
67.76
Low 80.00 +18.1%
Consensus 144.83 +113.7%
Median 145.50 +114.7%
High 192.00 +183.3%
Ratings Trend (MoM) 90% Bullish
Rating 2026-05 Change
Strong Buy 1 0
Buy 8 0
Hold 1 0
Sell 0 0
Strong Sell 0 0
Price Target Summary
Period # Analysts Avg Target
Last Month 2
140.00
+106.6%
Last Quarter 5
147.20
+117.2%
Last Year 10
131.10
+93.5%
All Time 14
98.43
+45.3%
Quality scores
Altman Z-Score
-1.68
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
2 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Biotechnology: +1.6%
    -43.9% Q1'26: +3.8% (vs Q1'25)
  • ✗
    EPS growth Biotechnology: +29.7%
    -12.1% Q1'26: +49.7% (vs Q1'25)
  • ✗
    FCF margin FCF growth · Biotechnology: +16.2%
    -349.4% Q1'26: -408.0% (vs Q1'25)
  • ✗
    EBIT margin Biotechnology: +0.0%
    -236.8% Q1'26: -352.3% (vs Q1'25)
  • ✓
    ROIC Biotechnology: -16.1%
    — Q1'26: -101.3% (vs Q1'25)
  • ✗
    Share dilution Biotechnology: -3.4%
    +23.1% Q1'26: +75.9% (vs Q1'25)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×
    -1.15× Q1'26: -0.94× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (1.25) × ERP
WACC = 90% × Ke + 10% × Kd (17.6%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Current price: 67.76
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2011
actual 		Dec 2012
actual 		Dec 2013
actual 		Dec 2014
actual 		Dec 2015
actual 		Dec 2016
actual 		Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
7 Rev. Ana.
7 EPS Ana. 		Dec 2027
8 Rev. Ana.
7 EPS Ana. 		Dec 2028
9 Rev. Ana.
9 EPS Ana. 		Dec 2029
4 Rev. Ana.
3 EPS Ana. 		Dec 2030
4 Rev. Ana.
3 EPS Ana.
Revenue
71.48M
est: 97.82M (-26.9%)
81.19M
est: 83.76M (-3.1%)
148.92M
est: 169.03M (-11.9%)
200.71M
est: 175.10M (+14.6%)
230.78M
est: 220.96M (+4.4%)
165.44M
est: 168.66M (-1.9%)
307.71M
est: 249.15M (+23.5%)
1.19B
est: 1.18B (+1.1%)
114.62M
est: 108.26M (+5.9%)
152.92M
est: 159.25M (-4.0%)
101.91M
est: 111.04M (-8.2%)
92.06M
est: 91.46M (+0.6%)
90.12M
est: 93.16M (-3.3%)
98.43M
est: 104.74M (-6.0%)
55.23M
est: 43.55M (+26.8%)
41.55M
39.66M – 43.16M
-4.6% YoY
35.88M
8.80M – 42.88M
-13.6% YoY
52.60M
27.58M – 59.27M
+46.6% YoY
94.94M
49.78M – 106.98M
+80.5% YoY
199.31M
104.51M – 224.58M
+109.9% YoY
EBITDA
-107.79M
est: -116.86M (+7.8%)
-124.10M
est: -124.94M (+0.7%)
-106.01M
est: -86.64M (-22.3%)
-2.74M
est: -33.19M (+91.7%)
-29.37M
est: -215.69M (+86.4%)
-97.27M
est: -164.64M (+40.9%)
-42.52M
est: -243.21M (+82.5%)
734.30M
est: 704.90M (+4.2%)
-382.70M
est: -427.60M (+10.5%)
-394.33M
est: -436.21M (+9.6%)
-461.82M
est: -489.69M (+5.7%)
-323.87M
est: -554.00M (+41.5%)
-243.11M
est: -90.94M (-167.3%)
-86.70M
est: -102.24M (+15.2%)
-129.74M
est: -42.52M (-205.2%)
-40.56M
-42.13M – -38.72M
+4.6% YoY
-35.03M
-41.86M – -8.59M
+13.6% YoY
-51.34M
-57.86M – -26.92M
-46.6% YoY
-92.67M
-104.43M – -48.59M
-80.5% YoY
-194.56M
-219.23M – -102.02M
-109.9% YoY
EBIT
-122.74M
est: -134.39M (+8.7%)
-137.90M
est: -143.11M (+3.6%)
-119.01M
est: -101.87M (-16.8%)
-15.67M
est: -46.13M (+66.0%)
-41.77M
est: -217.66M (+80.8%)
-110.47M
est: -166.14M (+33.5%)
-55.12M
est: -245.44M (+77.5%)
725.50M
est: 653.75M (+11.0%)
-393.70M
est: -494.81M (+20.4%)
-406.83M
est: -472.65M (+13.9%)
-475.97M
est: -473.76M (-0.5%)
-336.07M
est: -584.44M (+42.5%)
-250.92M
est: -91.77M (-173.4%)
-91.09M
est: -103.18M (+11.7%)
-130.77M
est: -42.90M (-204.8%)
-40.93M
-42.51M – -39.07M
+4.6% YoY
-35.35M
-42.24M – -8.67M
+13.6% YoY
-51.81M
-58.38M – -27.17M
-46.6% YoY
-93.52M
-105.38M – -49.04M
-80.5% YoY
-196.34M
-221.24M – -102.95M
-109.9% YoY
Net Income
-133.98M
est: -145.75M (+8.1%)
-171.86M
est: -174.58M (+1.6%)
-162.01M
est: -140.89M (-15.0%)
-53.92M
est: -81.29M (+33.7%)
-81.18M
est: -8.32M (-875.9%)
-153.52M
est: -224.46M (+31.6%)
-96.69M
est: -156.66M (+38.3%)
681.31M
est: 648.71M (+5.0%)
-440.67M
est: -495.42M (+11.1%)
-444.44M
est: -493.94M (+10.0%)
-523.84M
est: -555.71M (+5.7%)
-368.20M
est: -306.88M (-20.0%)
-276.06M
est: -11.77M (-2,245.3%)
-118.96M
est: -122.27M (+2.7%)
-164.08M
est: -164.08M (+0.0%)
-159.45M
-189.18M – -129.72M
+2.8% YoY
-203.88M
-232.77M – -174.99M
-27.9% YoY
-223.37M
-308.64M – -138.10M
-9.6% YoY
-177.24M
-206.46M – -67.65M
+20.7% YoY
-142.76M
-166.29M – -54.49M
+19.5% YoY
SGA
46.76M
est: 51.66M (-9.5%)
41.61M
est: 42.52M (-2.1%)
40.53M
est: 39.20M (+3.4%)
40.93M
est: 38.93M (+5.1%)
43.27M
est: 200.27M (-78.4%)
44.28M
est: 152.86M (-71.0%)
52.36M
est: 225.82M (-76.8%)
81.44M
est: 83.95M (-3.0%)
98.71M
est: 98.12M (+0.6%)
104.68M
est: 118.51M (-11.7%)
122.84M
est: 100.64M (+22.1%)
92.33M
est: 82.90M (+11.4%)
77.42M
est: 94.85M (-18.4%)
76.75M
est: 106.64M (-28.0%)
68.67M
est: 44.34M (+54.9%)
42.30M
40.38M – 43.94M
-4.6% YoY
36.53M
8.96M – 43.66M
-13.6% YoY
53.55M
28.08M – 60.34M
+46.6% YoY
96.66M
50.68M – 108.91M
+80.5% YoY
202.92M
106.41M – 228.66M
+109.9% YoY
EPS
-17.85
est: -1.66 (-978.5%)
-22.50
est: -1.54 (-1,361.0%)
-21.00
est: -1.25 (-1,586.7%)
-6.30
est: -0.85 (-641.2%)
-9.15
est: -0.61 (-1,408.2%)
-16.50
est: -16.37 (-0.8%)
-9.30
est: -11.43 (+18.6%)
56.70
est: 56.38 (+0.6%)
-37.80
est: -37.78 (0.0%)
-37.33
est: -37.50 (+0.5%)
-42.90
est: -43.44 (+1.2%)
-29.51
est: -31.89 (+7.5%)
-21.79
est: -0.90 (-2,315.0%)
-8.68
est: -10.75 (+19.3%)
-9.73
est: -9.93 (+2.0%)
-9.17
-11.21 – -7.69
+7.6% YoY
-11.17
-13.80 – -10.37
-21.8% YoY
-11.41
-18.29 – -8.19
-2.2% YoY
-10.51
-12.24 – -4.01
+7.9% YoY
-8.46
-9.86 – -3.23
+19.5% YoY
Recent Grade Changes (3M)
Date Firm Previous New Grade Action
2026-04-21 Wedbush Neutral Neutral Maintain
2026-04-20 HC Wainwright & Co. Buy Buy Maintain
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-07 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-06 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-05 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-04 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-01 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-30 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-29 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-28 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-27 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-24 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-23 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-22 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-21 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-20 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-17 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-16 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
-251.74M
OE per share TTM
-16.30
Owner's Yield
-12.21%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
99.7%

Ownership Overview

Ownership breakdown
At a glance
Institutional holders
29
Total invested
32.59M
Insider transactions (90d)
0
Beneficial owners (>5%)
25
Beneficial owners (>5%)
# Reporting person ⇅ Amount owned ⇅ % of class ⇅ Sole voting ⇅ Shared voting ⇅ Sole dispositive ⇅ Shared dispositive ⇅ Type Citizenship Filing date ⇅ SEC filing
1 98-0557567 36.89M 20.00% 36.83M — 36.89M — IA, HC Bermuda 2022-02-11 ↗
2 Chen Yu 20.05M 9.90% — 20.05M — 20.05M IN Delaware 2024-03-15 ↗
3 TCG Crossover Fund II, L.P. 20.05M 9.90% — 20.05M — 20.05M PN Delaware 2024-03-15 ↗
4 TCG Crossover GP II, LLC 20.05M 9.90% — 20.05M — 20.05M OO Delaware 2024-03-15 ↗
5 Peter Kolchinsky 18.70M 9.80% — 18.70M — 18.70M HC, IN Delaware 2023-08-17 ↗
6 RA Capital Healthcare Fund, L.P. 18.70M 9.80% — 18.70M — 18.70M PN Delaware 2023-08-17 ↗
7 RA Capital Management, L.P. 18.70M 9.80% — 18.70M — 18.70M IA, PN Delaware 2023-08-17 ↗
8 Rajeev Shah 18.70M 9.80% — 18.70M — 18.70M HC, IN Delaware 2023-08-17 ↗
9 The Vanguard Group - 23-1945930 18.51M 10.03% — 85.8K 18.26M 251.2K IA Pennsylvania 2022-01-10 ↗
10 PRIMECAP Management Company 95-3868081 18.44M 10.28% 18.31M — 18.44M — IA 177 E. Colorado Blvd., 11th Floor, Pasadena, CA 91105 2021-02-12 ↗
11 PRIMECAP Management Company 17.41M 9.43% 17.25M — 17.41M — IA 177 E. Colorado Blvd., 11th Floor, Pasadena, CA 91105 2022-02-10 ↗
12 (1) BlackRock, Inc. 15.97M 8.70% 15.41M — — 15.41M HC Delaware 2024-11-08 ↗
13 Abigail P. Johnson 14.94M 8.49% — — 14.94M — IN Delaware 2020-02-07 ↗
14 David Kroin 12.30M 6.50% — 12.30M — — HC, IN Delaware 2023-04-14 ↗
15 Deep Track Biotechnology Master Fund, Ltd. 12.30M 6.50% — 12.30M — — CO Delaware 2023-04-14 ↗
16 Deep Track Capital, LP 12.30M 6.50% — 12.30M — — IA, OO Delaware 2023-04-14 ↗
17 Wellington Group Holdings LLP 11.38M 6.17% — 11.38M — — HC Delaware 2022-02-04 ↗
18 Wellington Investment Advisors Holdings LLP 11.38M 6.17% — 11.38M — — HC Delaware 2022-02-04 ↗
19 Wellington Management Company LLP 11.38M 6.17% — 11.38M — — IA Delaware 2022-02-04 ↗
20 Wellington Management Group LLP 11.38M 6.17% — 11.38M — — HC Massachusetts 2022-02-04 ↗
21 FMR LLC 9.47M 5.13% 2.61M — 9.47M — HC Delaware 2021-12-10 ↗
22 Eventide Asset Management, LLC 9.40M 5.11% 9.40M — 9.40M — IA Delaware 2024-11-14 ↗
23 Finny Kuruvilla, M.D. Ph. D. 9.40M 5.11% — 9.40M — — HC, IN Delaware 2024-11-14 ↗
24 Robin C. John 9.40M 5.11% — 9.40M — — HC, IN Delaware 2024-11-14 ↗
25 Citadel Securities Group LP 6.00 1.20% — 7.50M — — HC, PN Delaware 2023-07-03 ↗

Institutional Activity (13F)

Institutional ownership trend From To
13F snapshot — 2026 Q1
Investors holding
29
-157 vs prev Q
New positions
12
Closed positions
158
Increased
18
Reduced
7
Put/Call ratio
0.00
Calls held
202.5K
Puts held
—
Top institutional holders
# Investor ⇅ Shares / Δ ⇅ Mkt value / Δ ⇅ Own% / Δ ⇅ Weight% / Δ ⇅ Avg px / Perf. ⇅ Hold / Status ⇅
1 BVF INC/IL 1.56M +283.0K (+22.2%) 65.94M -6.7M (-9.2%) 11.07% +2.009 pp 2.22% -0.725 pp USD54.25 -22.1% 2 qtrs —
2 VANGUARD GROUP INC 1.03M +78.4K (+8.3%) 43.43M -10.6M (-19.6%) 7.29% +0.557 pp 0.00% 0.000 pp USD33.72 +25.4% 3 qtrs —
3 TWO SEAS CAPITAL LP 745.2K +745.2K (+100.0%) 31.51M +31.5M (+100.0%) 5.29% +5.290 pp 0.65% +0.649 pp USD42.28 +0.0% 1 qtrs NEW
4 BLACKROCK, INC. 645.6K +36.5K (+6.0%) 27.30M -7.4M (-21.2%) 4.58% +0.259 pp 0.00% 0.000 pp USD36.10 +17.1% 3 qtrs —
5 ARMISTICE CAPITAL, LLC 596.0K +328.0K (+122.4%) 25.20M +9.9M (+65.2%) 4.23% +2.328 pp 0.30% +0.074 pp USD42.39 -0.3% 3 qtrs —
6 MORGAN STANLEY 566.4K -362.7K (-39.0%) 23.95M -28.9M (-54.7%) 4.02% -2.575 pp 0.00% -0.002 pp USD54.49 -22.4% 3 qtrs —
7 PROSIGHT MANAGEMENT, LP 554.6K +554.6K (+100.0%) 23.45M +23.4M (+100.0%) 3.94% +3.937 pp 4.85% +4.846 pp USD42.28 +0.0% 1 qtrs NEW
8 TWO SIGMA INVESTMENTS, LP 473.0K +38.8K (+8.9%) 20.00M -4.7M (-19.1%) 3.36% +0.275 pp 0.03% -0.009 pp USD50.49 -16.3% 3 qtrs —
9 INVESCO LTD. 468.2K +241.3K (+106.3%) 19.79M +6.9M (+53.3%) 3.32% +1.713 pp 0.00% +0.001 pp USD47.24 -10.5% 3 qtrs —
10 MILLENNIUM MANAGEMENT LLC 454.1K -91.9K (-16.8%) 19.20M -11.9M (-38.2%) 3.22% -0.653 pp 0.01% -0.005 pp USD25.84 +63.6% 3 qtrs —
11 SOFINNOVA INVESTMENTS, INC. 438.6K +320.2K (+270.4%) 18.55M +11.8M (+175.2%) 3.11% +2.273 pp 0.80% +0.431 pp USD46.23 -8.5% 2 qtrs —
12 POINT72 ASSET MANAGEMENT, L.P. 433.4K +309.8K (+250.5%) 18.32M +11.3M (+160.4%) 3.08% +2.199 pp 0.02% +0.009 pp USD46.45 -9.0% 2 qtrs —
13 SUSQUEHANNA INTERNATIONAL GROUP, LLP 410.6K +99.6K (+32.0%) 17.36M -335.7K (-1.9%) 2.91% +0.707 pp 0.00% +0.000 pp USD29.83 +41.7% 3 qtrs —
14 EMERALD ADVISERS, LLC 384.3K +61.1K (+18.9%) 16.25M -2.1M (-11.6%) 2.73% +0.434 pp 0.50% -0.089 pp USD54.58 -22.5% 2 qtrs —
15 22NW, LP 331.1K +— (+0.0%) 14.00M -4.8M (-25.7%) 2.35% +0.000 pp 5.89% -2.984 pp USD43.19 -2.1% 3 qtrs —
16 QUBE RESEARCH & TECHNOLOGIES LTD 323.9K +319.9K (+8,050.9%) 13.70M +13.5M (+5,956.5%) 2.30% +2.271 pp 0.01% +0.014 pp USD42.46 -0.4% 2 qtrs —
17 TWO SIGMA ADVISERS, LP 308.4K +129.5K (+72.4%) 13.04M +2.9M (+28.1%) 2.19% +0.919 pp 0.03% +0.005 pp USD50.76 -16.7% 2 qtrs —
18 VOLORIDGE INVESTMENT MANAGEMENT, LLC 295.7K +123.9K (+72.2%) 12.50M +2.7M (+27.9%) 2.10% +0.880 pp 0.04% +0.011 pp USD50.77 -16.7% 2 qtrs —
19 UBS GROUP AG 287.6K +196.7K (+216.6%) 12.16M +7.0M (+135.3%) 2.04% +1.397 pp 0.00% +0.001 pp USD37.09 +14.0% 3 qtrs —
20 BALYASNY ASSET MANAGEMENT L.P. 282.0K +99.2K (+54.3%) 11.92M +1.5M (+14.6%) 2.00% +0.704 pp 0.02% +0.002 pp USD31.62 +33.7% 3 qtrs —
21 PRIMECAP MANAGEMENT CO/CA/ 280.2K -8.9K (-3.1%) 11.84M -4.6M (-28.0%) 1.99% -0.063 pp 0.01% -0.004 pp USD25.84 +63.6% 3 qtrs —
22 GEODE CAPITAL MANAGEMENT, LLC 254.4K +29.1K (+12.9%) 10.76M -2.1M (-16.1%) 1.81% +0.207 pp 0.00% 0.000 pp USD39.06 +8.2% 3 qtrs —
23 EMERALD MUTUAL FUND ADVISERS TRUST 253.1K +19.9K (+8.5%) 10.70M -2.6M (-19.3%) 1.80% +0.141 pp 0.52% -0.164 pp USD55.75 -24.2% 2 qtrs —
24 JANE STREET GROUP, LLC 218.3K +218.3K (+100.0%) 9.23M +9.2M (+100.0%) 1.55% +1.550 pp 0.00% +0.001 pp USD42.28 +0.0% 1 qtrs NEW
25 GREAT POINT PARTNERS LLC 210.7K -89.3K (-29.8%) 8.91M -8.2M (-47.8%) 1.50% -0.634 pp 2.89% -4.150 pp USD56.90 -25.7% 2 qtrs —
26 BNP PARIBAS ARBITRAGE, SNC 210.3K +209.9K (+48,355.8%) 8.89M +8.9M (+35,904.9%) 1.49% +1.490 pp 0.00% +0.004 pp USD42.28 +0.0% 3 qtrs —
27 GILDER GAGNON HOWE & CO LLC 208.3K -16.5K (-7.4%) 8.81M -4.0M (-31.2%) 1.48% -0.117 pp 0.09% -0.037 pp USD52.91 -20.1% 3 qtrs —
28 STATE STREET CORP 195.7K +66.7K (+51.7%) 8.27M +932.3K (+12.7%) 1.39% +0.473 pp 0.00% +0.000 pp USD43.97 -3.8% 3 qtrs —
29 NATIONALE-NEDERLANDEN POWSZECHNE TOWARZYSTWO EMERYTALNE S.A. 188.1K +34.3K (+22.3%) 7.95M -800.5K (-9.1%) 1.34% +0.243 pp 0.71% +0.029 pp USD54.24 -22.1% 2 qtrs —
30 — 185.5K +185.5K (+100.0%) 7.84M +7.8M (+100.0%) 1.32% +1.317 pp 5.47% +5.472 pp USD42.28 +0.0% 1 qtrs NEW
31 STEMPOINT CAPITAL LP 178.3K +125.1K (+235.1%) 7.54M +4.5M (+149.0%) 1.27% +0.888 pp 1.29% +0.686 pp USD46.64 -9.3% 2 qtrs —
32 HRT FINANCIAL LP 173.4K +160.3K (+1,218.2%) 7.33M +6.6M (+880.3%) 1.23% +1.138 pp 0.02% +0.020 pp USD43.39 -2.6% 2 qtrs —
33 RENAISSANCE TECHNOLOGIES LLC 172.9K -105.7K (-37.9%) 7.31M -8.5M (-53.9%) 1.23% -0.750 pp 0.01% -0.010 pp USD29.35 +44.1% 3 qtrs —
34 JPMORGAN CHASE & CO 150.8K +150.8K (+793,605.3%) 6.38M +6.4M (+589,723.6%) 1.07% +1.070 pp 0.00% +0.000 pp USD42.28 +0.0% 3 qtrs —
35 GOLDMAN SACHS GROUP INC 147.8K +70.7K (+91.8%) 6.25M +1.9M (+42.5%) 1.05% +0.502 pp 0.00% +0.000 pp USD36.78 +15.0% 3 qtrs —
36 CHARLES SCHWAB INVESTMENT MANAGEMENT INC 120.4K +5.7K (+5.0%) 5.09M -1.4M (-22.0%) 0.85% +0.041 pp 0.00% 0.000 pp USD39.20 +7.9% 3 qtrs —
37 NANTAHALA CAPITAL MANAGEMENT, LLC 112.9K -305.6K (-73.0%) 4.78M -19.0M (-79.9%) 0.80% -2.169 pp 0.16% -0.669 pp USD25.84 +63.6% 3 qtrs —
38 JEFFERIES FINANCIAL GROUP INC. 111.9K -191.3K (-63.1%) 4.73M -12.5M (-72.6%) 0.79% -1.358 pp 0.02% -0.057 pp USD56.90 -25.7% 2 qtrs —
39 WOODLINE PARTNERS LP 104.0K -129.1K (-55.4%) 4.40M -8.9M (-66.8%) 0.74% -0.916 pp 0.02% -0.045 pp USD25.84 +63.6% 3 qtrs —
40 CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. 101.2K +52.5K (+108.1%) 4.28M +1.5M (+54.6%) 0.72% +0.373 pp 0.01% +0.003 pp USD42.76 -1.1% 3 qtrs —
41 FMR LLC 101.1K +61.2K (+153.0%) 4.28M +2.0M (+88.0%) 0.72% +0.434 pp 0.00% +0.000 pp USD43.37 -2.5% 3 qtrs —
42 ING GROEP NV 100.0K +100.0K (+100.0%) 4.23M +4.2M (+100.0%) 0.71% +0.710 pp 0.03% +0.026 pp USD42.28 +0.0% 1 qtrs NEW
43 MONASHEE INVESTMENT MANAGEMENT LLC 94.1K +94.1K (+100.0%) 3.98M +4.0M (+100.0%) 0.67% +0.668 pp 2.24% +2.243 pp USD42.28 +0.0% 1 qtrs NEW
44 CITADEL ADVISORS LLC 91.6K -42.7K (-31.8%) 3.87M -3.8M (-49.3%) 0.65% -0.303 pp 0.00% -0.001 pp USD25.84 +63.6% 3 qtrs —
45 DEUTSCHE BANK AG\ 90.7K +743.0 (+0.8%) 3.84M -1.3M (-25.1%) 0.64% +0.005 pp 0.00% -0.001 pp USD56.78 -25.5% 2 qtrs —
46 QUINN OPPORTUNITY PARTNERS LLC 85.9K -24.0K (-21.8%) 3.63M -2.6M (-41.9%) 0.61% -0.170 pp 0.15% -0.290 pp USD56.90 -25.7% 2 qtrs —
47 RUSSELL INVESTMENTS GROUP, LTD. 85.7K +68.6K (+402.5%) 3.62M +2.7M (+273.3%) 0.61% +0.487 pp 0.00% +0.003 pp USD43.36 -2.5% 3 qtrs —
48 STONEPINE CAPITAL MANAGEMENT, LLC 85.0K +— (+0.0%) 3.59M -1.2M (-25.7%) 0.60% +0.000 pp 2.62% -1.308 pp USD38.56 +9.6% 3 qtrs —
49 PROPEL BIO MANAGEMENT, LLC 82.8K +33.8K (+69.0%) 3.50M +713.6K (+25.6%) 0.59% +0.240 pp 2.99% +0.199 pp USD50.93 -17.0% 2 qtrs —
50 DAFNA CAPITAL MANAGEMENT LLC 75.0K +20.0K (+36.4%) 3.17M +41.5K (+1.3%) 0.53% +0.142 pp 0.74% -0.037 pp USD48.86 -13.5% 3 qtrs —
51 ACADIAN ASSET MANAGEMENT LLC 72.2K +44.9K (+164.3%) 3.05M +1.5M (+96.4%) 0.51% +0.319 pp 0.01% +0.002 pp USD36.06 +17.2% 3 qtrs —
52 ADAR1 CAPITAL MANAGEMENT, LLC 72.0K +24.0 (+0.0%) 3.05M -1.1M (-25.7%) 0.51% +0.000 pp 0.22% -0.161 pp USD50.08 -15.6% 3 qtrs —
53 TFG ASSET MANAGEMENT GP LTD 69.3K +69.3K (+100.0%) 2.93M +2.9M (+100.0%) 0.49% +0.492 pp 0.62% +0.618 pp USD42.28 +0.0% 1 qtrs NEW
54 VOLEON CAPITAL MANAGEMENT LP 68.3K +68.3K (+100.0%) 2.89M +2.9M (+100.0%) 0.49% +0.485 pp 0.06% +0.062 pp USD42.28 +0.0% 1 qtrs NEW
55 NEARWATER CAPITAL MARKETS, LTD 61.5K +61.5K (+100.0%) 2.60M +2.6M (+100.0%) 0.44% +0.437 pp 0.04% +0.045 pp USD42.28 +0.0% 1 qtrs NEW
56 LANDSCAPE CAPITAL MANAGEMENT, L.L.C. 60.4K +60.4K (+100.0%) 2.56M +2.6M (+100.0%) 0.43% +0.429 pp 0.17% +0.171 pp USD42.28 +0.0% 1 qtrs NEW
57 HUDSON BAY CAPITAL MANAGEMENT LP 59.7K -48.0K (-44.6%) 2.52M -3.6M (-58.8%) 0.42% -0.341 pp 0.01% -0.012 pp USD56.90 -25.7% 2 qtrs —
58 F/M INVESTMENTS LLC 58.1K +5.0K (+9.5%) 2.46M -563.3K (-18.6%) 0.41% +0.036 pp 0.09% -0.023 pp USD55.63 -24.0% 2 qtrs —
59 NORTHERN TRUST CORP 56.1K +17.6K (+45.7%) 2.37M +180.8K (+8.3%) 0.40% +0.125 pp 0.00% +0.000 pp USD38.94 +8.6% 3 qtrs —
60 MOODY ALDRICH PARTNERS LLC 56.0K -17.7K (-24.0%) 2.37M -1.8M (-43.5%) 0.40% -0.126 pp 0.44% -0.354 pp USD37.77 +11.9% 3 qtrs —
61 AQUATIC CAPITAL MANAGEMENT LLC 55.2K +55.2K (+100.0%) 2.34M +2.3M (+100.0%) 0.39% +0.392 pp 0.07% +0.066 pp USD42.28 +0.0% 1 qtrs NEW
62 FRED ALGER MANAGEMENT, LLC 54.0K -37.8K (-41.2%) 2.28M -2.9M (-56.3%) 0.38% -0.268 pp 0.01% -0.011 pp USD39.07 +8.2% 3 qtrs —
63 CAMBRIDGE INVESTMENT RESEARCH ADVISORS, INC. 53.7K +7.1K (+15.2%) 2.27M -383.0K (-14.4%) 0.38% +0.050 pp 0.01% -0.001 pp USD47.99 -11.9% 3 qtrs —
64 JUMP FINANCIAL, LLC 53.2K +53.2K (+100.0%) 2.25M +2.2M (+100.0%) 0.38% +0.378 pp 0.03% +0.028 pp USD42.28 +0.0% 1 qtrs NEW
65 ACT CAPITAL MANAGEMENT, LLC 51.2K +51.2K (+100.0%) 2.16M +2.2M (+100.0%) 0.36% +0.363 pp 1.75% +1.750 pp USD42.28 +0.0% 1 qtrs NEW
66 NORGES BANK 50.0K +50.0K (+100.0%) 2.11M +2.1M (+100.0%) 0.35% +0.355 pp 0.00% +0.000 pp USD42.28 +0.0% 1 qtrs NEW
67 DARK FOREST CAPITAL MANAGEMENT LP 42.3K +33.1K (+360.3%) 1.79M +1.3M (+242.0%) 0.30% +0.235 pp 0.08% +0.066 pp USD45.46 -7.0% 2 qtrs —
68 HEADLANDS TECHNOLOGIES LLC 41.2K +11.4K (+38.1%) 1.74M +44.7K (+2.6%) 0.29% +0.081 pp 0.15% +0.010 pp USD50.96 -17.0% 3 qtrs —
69 AWM INVESTMENT COMPANY, INC. 40.0K +— (+0.0%) 1.69M -584.8K (-25.7%) 0.28% +0.000 pp 0.16% -0.050 pp USD56.90 -25.7% 2 qtrs —
70 DEUTERIUM CAPITAL MANAGEMENT, LLC 37.3K +— (+0.0%) 1.58M -546.0K (-25.7%) 0.27% +0.000 pp 2.29% -0.786 pp USD25.84 +63.6% 3 qtrs —
71 ENGINEERS GATE MANAGER LP 37.3K +19.7K (+111.5%) 1.58M +573.2K (+57.1%) 0.26% +0.140 pp 0.02% +0.007 pp USD49.19 -14.0% 2 qtrs —
72 IKARIAN CAPITAL, LLC 36.3K +36.3K (+100.0%) 1.53M +1.5M (+100.0%) 0.26% +0.258 pp 0.12% +0.120 pp USD42.28 +0.0% 1 qtrs NEW
73 CITIGROUP INC 35.8K +32.7K (+1,074.2%) 1.51M +1.3M (+772.5%) 0.25% +0.232 pp 0.00% +0.001 pp USD40.88 +3.4% 3 qtrs —
74 CAPTION MANAGEMENT, LLC 35.0K +35.0K (+100.0%) 1.48M +1.5M (+100.0%) 0.25% +0.249 pp 0.01% +0.010 pp USD42.28 +0.0% 3 qtrs —
75 SWISS NATIONAL BANK 31.9K +31.9K (+100.0%) 1.35M +1.3M (+100.0%) 0.23% +0.226 pp 0.00% +0.001 pp USD42.28 +0.0% 1 qtrs NEW
76 SUMMITTX CAPITAL, L.P. 31.4K +24.6K (+361.2%) 1.33M +938.8K (+242.7%) 0.22% +0.174 pp 0.04% +0.024 pp USD38.72 +9.2% 3 qtrs —
77 BIRCHVIEW CAPITAL, LP 31.0K +27.0K (+671.0%) 1.31M +1.1M (+472.9%) 0.22% +0.192 pp 0.77% +0.595 pp USD44.18 -4.3% 2 qtrs —
78 ERSTE ASSET MANAGEMENT GMBH 28.0K +11.0K (+64.7%) 1.20M +194.8K (+19.4%) 0.20% +0.078 pp 0.01% +0.000 pp USD51.16 -17.4% 2 qtrs —
79 SIMPLIFY ASSET MANAGEMENT INC. 28.0K -59.2K (-67.9%) 1.18M -3.8M (-76.1%) 0.20% -0.420 pp 0.02% -0.072 pp USD38.37 +10.2% 3 qtrs —
80 FOX RUN MANAGEMENT, L.L.C. 26.5K +26.5K (+100.0%) 1.12M +1.1M (+100.0%) 0.19% +0.188 pp 0.17% +0.173 pp USD42.28 +0.0% 1 qtrs NEW
81 BANK OF AMERICA CORP /DE/ 26.1K -21.9K (-45.6%) 1.10M -1.6M (-59.6%) 0.19% -0.155 pp 0.00% 0.000 pp USD25.84 +63.6% 3 qtrs —
82 MARSHALL WACE, LLP 24.0K +24.0K (+100.0%) 1.02M +1.0M (+100.0%) 0.17% +0.171 pp 0.00% +0.001 pp USD42.28 +0.0% 3 qtrs —
83 GSA CAPITAL PARTNERS LLP 23.1K +23.1K (+100.0%) 977.0K +977.0K (+100.0%) 0.16% +0.164 pp 0.08% +0.084 pp USD42.28 +0.0% 1 qtrs NEW
84 SIMPLEX TRADING, LLC 21.9K -54.5K (-71.3%) 927.5K -3.4M (-78.7%) 0.16% -0.387 pp 0.00% -0.002 pp USD37.82 +11.8% 3 qtrs —
85 BIT CAPITAL GMBH 21.1K +21.1K (+100.0%) 892.1K +892.1K (+100.0%) 0.15% +0.150 pp 0.03% +0.033 pp USD42.28 +0.0% 1 qtrs NEW
86 SQUAREPOINT OPS LLC 20.3K -14.2K (-41.3%) 856.5K -1.1M (-56.4%) 0.14% -0.101 pp 0.00% -0.001 pp USD56.90 -25.7% 2 qtrs —
87 TREXQUANT INVESTMENT LP 18.8K -72.7K (-79.4%) 795.8K -4.4M (-84.7%) 0.13% -0.516 pp 0.01% -0.047 pp USD56.90 -25.7% 2 qtrs —
88 J. GOLDMAN & CO LP 18.4K +18.4K (+100.0%) 775.9K +775.9K (+100.0%) 0.13% +0.130 pp 0.02% +0.020 pp USD42.28 +0.0% 1 qtrs NEW
89 JAIN GLOBAL LLC 17.3K -15.5K (-47.2%) 731.4K -1.1M (-60.8%) 0.12% -0.110 pp 0.00% -0.005 pp USD25.84 +63.6% 3 qtrs —
90 UBS ASSET MANAGEMENT AMERICAS INC 16.2K +16.2K (+100.0%) 684.3K +684.3K (+100.0%) 0.11% +0.115 pp 0.00% +0.000 pp USD42.28 +0.0% 1 qtrs NEW
91 SUSQUEHANNA PORTFOLIO STRATEGIES, LLC 16.1K +— (+0.0%) 678.9K -234.8K (-25.7%) 0.11% +0.000 pp 0.01% -0.004 pp USD56.90 -25.7% 2 qtrs —
Ownership breakdown by holder

ETF Ownership

Top ETFs holding this stock Held by 81 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 F/M Emerald Life Sciences Innovation ETF LFSC 2.90% 2.16M 0.54%
2 F/m Emerald Special Situations ETF SPIT 1.96% 568.4K 0.89%
3 State Street SPDR S&P Pharmaceuticals ETF XPH 1.86% 8.77M 0.35%
4 Militia Long/Short Equity ETF ORR 1.24% 1.72M 14.19%
5 ALPS Medical Breakthroughs ETF SBIO 1.21% 2.59M 0.50%
6 Virtus Biotech Clinical Trials ETF BBC 0.73% 419.8K 0.65%
7 Invesco NASDAQ Future Gen 200 ETF QQQS 0.54% 119.0K 0.20%
8 iShares U.S. Pharmaceuticals ETF IHE 0.54% 7.18M 0.38%
9 Direxion Daily Pharmaceutical & Medical Bull 3X ETF PILL 0.39% 90.1K 1.22%
10 Invesco RAFI US 1500 Small-Mid ETF PRFZ 0.15% 4.15M 0.34%

Insider Activity

Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Ratio by volume
0.00
Bearish
Buys
0
Sells
3
Shares acquired
—
Shares disposed
4.5K
Cash buys
—
Cash sales
3.00
Net activity
-4,470
Insider buys vs sells (history) From To
Recent insider transactions From To
Date Person Role Transaction A/D Security Shares Price Value Owned after D/I Filing
2026-02-18 Zalevsky Jonathan Officer S-Sale D Common Stock 180 73.00 13.1K 21,174 D ↗
2026-02-18 ROBIN HOWARD W Director / Officer S-Sale D Common Stock 423 73.00 30.9K 75,489 D ↗
2026-01-20 Zalevsky Jonathan Officer S-Sale D Common Stock 3,867 35.67 137.9K 21,354 D ↗
2025-12-22 Zalevsky Jonathan Officer A-Award A Common Stock 6,250 0.00 — 25,221 D ↗
2025-12-22 ROBIN HOWARD W Director / Officer A-Award A Stock Option 86,667 43.48 3.77M 86,667 D ↗
2025-11-25 Zalevsky Jonathan Officer S-Sale D Common Stock 1,157 54.28 62.8K 18,971 D ↗
2025-11-25 Wilson Mark Andrew Officer S-Sale D Common Stock 630 54.28 34.2K 21,585 D ↗
2025-11-25 ROBIN HOWARD W Director / Officer S-Sale D Common Stock 2,207 54.28 119.8K 54,245 D ↗
2025-11-21 Zalevsky Jonathan Officer A-Award A Stock Option 4,766 281.25 1.34M 4,766 D ↗
2025-11-21 Wilson Mark Andrew Officer A-Award A Stock Option 3,400 281.25 956.3K 3,400 D ↗
2025-11-21 ROBIN HOWARD W Director / Officer A-Award A Common Stock 7,110 0.00 — 56,452 D ↗
2025-09-30 WHITFIELD ROY A Director A-Award A Stock Option 8,000 56.90 455.2K 8,000 D ↗
2025-09-30 GREER R SCOTT Director A-Award A Stock Option 8,000 56.90 455.2K 8,000 D ↗
2025-09-30 CHESS ROBERT Director A-Award A Stock Option 8,000 56.90 455.2K 8,000 D ↗
2025-09-30 Brainard Diana Director A-Award A Stock Option 8,000 56.90 455.2K 8,000 D ↗
2025-09-30 Ajer Jeffrey Robert Director A-Award A Stock Option 8,000 56.90 455.2K 8,000 D ↗
2025-09-09 ROBIN HOWARD W Director / Officer S-Sale D Common Stock 2,100 45.16 94.8K 53,908 D ↗
2025-09-05 ROBIN HOWARD W Director / Officer S-Sale D Common Stock 1,136 39.89 45.3K 56,008 D ↗
2025-09-04 Zalevsky Jonathan Officer S-Sale D Common Stock 432 33.60 14.5K 17,958 D ↗
2025-09-04 ROBIN HOWARD W Director / Officer S-Sale D Common Stock 1,496 33.54 50.2K 64,421 D ↗
2025-09-02 Zalevsky Jonathan Officer S-Sale D Common Stock 485 30.10 14.6K 19,183 D ↗
2025-09-02 ROBIN HOWARD W Director / Officer S-Sale D Common Stock 1,500 30.16 45.2K 67,840 D ↗
2025-08-19 Zalevsky Jonathan Officer S-Sale D Common Stock 725 26.59 19.3K 19,668 D ↗
2025-08-19 Wilson Mark Andrew Officer A-Award A Stock Option 21,666 0.50 10.8K 21,666 D ↗
2025-08-19 ROBIN HOWARD W Director / Officer A-Award A Stock Option 86,666 0.50 43.3K 86,666 D ↗
2025-05-19 Zalevsky Jonathan Officer S-Sale D Common Stock 10,712 0.67 7.2K 305,892 D ↗
2025-05-19 Wilson Mark Andrew Officer S-Sale D Common Stock 9,996 0.67 6.7K 314,296 D ↗
2025-05-19 ROBIN HOWARD W Director / Officer S-Sale D Common Stock 23,208 0.67 15.5K 1,063,693 D ↗
2025-02-19 Zalevsky Jonathan Officer S-Sale D Common Stock 10,300 1.01 10.4K 316,604 D ↗
2025-02-19 Wilson Mark Andrew Officer S-Sale D Common Stock 11,040 1.01 11.2K 324,292 D ↗
2025-02-19 ROBIN HOWARD W Director / Officer S-Sale D Common Stock 23,774 1.01 24.0K 1,086,901 D ↗
2024-12-24 Wilson Mark Andrew Officer S-Sale D Common Stock 16,560 0.89 14.7K 335,332 D ↗
2024-12-23 Wilson Mark Andrew Officer S-Sale D Common Stock 33,402 0.90 30.1K 351,892 D ↗
2024-12-19 Zalevsky Jonathan Officer S-Sale D Common Stock 51,115 0.94 48.0K 326,904 D ↗
2024-12-18 ROBIN HOWARD W Director / Officer S-Sale D Common Stock 85,035 0.99 84.2K 1,110,675 D ↗
2024-12-17 ROBIN HOWARD W Director / Officer S-Sale D Common Stock 46,995 1.01 47.5K 1,195,710 D ↗
2024-12-13 Zalevsky Jonathan Officer A-Award A Common Stock 135,000 0.00 — 378,019 D ↗
2024-12-13 Wilson Mark Andrew Officer A-Award A Stock Option 325,000 1.01 328.3K 325,000 D ↗
2024-12-13 ROBIN HOWARD W Director / Officer A-Award A Stock Option 821,250 4.91 4.03M 821,250 D ↗
2024-11-19 Zalevsky Jonathan Officer S-Sale D Common Stock 7,785 1.01 7.9K 243,019 D ↗
2024-11-19 Wilson Mark Andrew Officer S-Sale D Common Stock 6,407 1.01 6.5K 218,856 D ↗
2024-11-19 ROBIN HOWARD W Director / Officer S-Sale D Common Stock 16,278 1.01 16.4K 832,080 D ↗
2024-09-18 WHITFIELD ROY A Director A-Award A Stock Option 120,000 1.26 151.2K 120,000 D ↗
2024-09-18 GREER R SCOTT Director A-Award A Stock Option 120,000 1.26 151.2K 120,000 D ↗
2024-09-18 CHESS ROBERT Director A-Award A Stock Option 120,000 1.26 151.2K 120,000 D ↗
2024-09-18 Brainard Diana Director A-Award A Stock Option 120,000 1.26 151.2K 120,000 D ↗
2024-09-18 Ajer Jeffrey Robert Director A-Award A Stock Option 120,000 1.26 151.2K 120,000 D ↗
2024-08-19 Zalevsky Jonathan Officer S-Sale D Common Stock 6,866 1.28 8.8K 250,804 — ↗
2024-08-19 Wilson Mark Andrew Officer S-Sale D Common Stock 5,651 1.28 7.2K 225,263 — ↗
2024-08-19 ROBIN HOWARD W Director / Officer S-Sale D Common Stock 14,881 1.28 19.0K 848,358 — ↗
2024-06-14 CHESS ROBERT Director S-Sale D Common Stock 19,500 1.20 23.4K 255,273 — ↗
2024-05-17 Zalevsky Jonathan Officer S-Sale D Common Stock 7,355 1.75 12.9K 257,670 — ↗
2024-05-17 Wilson Mark Andrew Officer S-Sale D Common Stock 6,260 1.75 11.0K 230,414 — ↗
2024-05-17 ROBIN HOWARD W Director / Officer S-Sale D Common Stock 16,650 1.75 29.1K 863,239 — ↗
2024-05-10 Deep Track Capital, LP 10% Owner S-Sale D Common Stock 56,000 1.78 99.6K 18,344,000 — ↗
2024-03-05 Deep Track Capital, LP 10% Owner — I Common Stock 0 0.00 — 18,400,000 — ↗
2024-02-20 Zalevsky Jonathan Officer S-Sale D Common Stock 9,014 0.68 6.1K 265,025 — ↗
2024-02-20 Wilson Mark Andrew Officer S-Sale D Common Stock 7,606 0.68 5.2K 236,674 — ↗
2024-02-20 ROBIN HOWARD W Director / Officer S-Sale D Common Stock 20,033 0.68 13.6K 879,889 — ↗
2023-12-13 Zalevsky Jonathan Officer A-Award A Stock Option 250,000 0.50 125.0K 250,000 — ↗
2023-12-13 Wilson Mark Andrew Officer A-Award A Stock Option 325,000 0.50 162.5K 325,000 — ↗
2023-12-13 ROBIN HOWARD W Director / Officer A-Award A Stock Option 1,300,000 0.50 650.0K 1,300,000 — ↗
2023-11-17 Zalevsky Jonathan Officer S-Sale D Common Stock 9,646 0.49 4.7K 274,039 — ↗
2023-11-17 Wilson Mark Andrew Officer S-Sale D Common Stock 7,179 0.49 3.5K 243,780 — ↗
2023-11-17 ROBIN HOWARD W Director / Officer S-Sale D Common Stock 19,877 0.49 9.7K 899,922 — ↗
2023-09-19 WHITFIELD ROY A Director A-Award A Stock Option 85,000 0.68 57.8K 85,000 — ↗
2023-09-19 GREER R SCOTT Director A-Award A Stock Option 85,000 0.68 57.8K 85,000 — ↗
2023-09-19 Curet Myriam Director A-Award A Stock Option 85,000 0.68 57.8K 85,000 — ↗
2023-09-19 CHESS ROBERT Director A-Award A Stock Option 85,000 0.68 57.8K 85,000 — ↗
2023-09-19 Brainard Diana Director A-Award A Stock Option 85,000 0.68 57.8K 85,000 — ↗
2023-09-19 Ajer Jeffrey Robert Director A-Award A Stock Option 85,000 0.68 57.8K 85,000 — ↗
2023-09-18 Curet Myriam Director S-Sale D Common Stock 4,359 0.69 3.0K 27,418 — ↗
2023-09-18 Ajer Jeffrey Robert Director S-Sale D Common Stock 4,359 0.69 3.0K 34,153 — ↗
2023-08-16 Zalevsky Jonathan Officer S-Sale D Common Stock 9,703 0.78 7.6K 283,685 — ↗
2023-08-16 Wilson Mark Andrew Officer S-Sale D Common Stock 7,221 0.78 5.6K 250,959 — ↗
2023-08-16 ROBIN HOWARD W Director / Officer S-Sale D Common Stock 19,998 0.78 15.6K 919,799 — ↗
2023-06-14 WHITFIELD ROY A Director S-Sale D Common Stock 30,000 0.57 17.1K 216,250 — ↗
2023-05-16 Zalevsky Jonathan Officer S-Sale D Common Stock 9,791 0.72 7.0K 293,388 — ↗
2023-05-16 Wilson Mark Andrew Officer S-Sale D Common Stock 7,543 0.72 5.4K 257,680 — ↗
2023-05-16 ROBIN HOWARD W Director / Officer S-Sale D Common Stock 20,361 0.72 14.7K 939,797 — ↗
2023-04-17 GARDINER SANDRA A. Officer — — — 0 0.00 — 0 — ↗
2023-02-16 Zalevsky Jonathan Officer S-Sale D Common Stock 10,484 3.00 31.5K 303,179 — ↗
2023-02-16 Wilson Mark Andrew Officer S-Sale D Common Stock 8,275 3.00 24.8K 265,223 — ↗
2023-02-16 Thomsen Jillian B. Officer S-Sale D Common Stock 10,267 3.00 30.8K 313,497 — ↗
2023-02-16 ROBIN HOWARD W Director / Officer S-Sale D Common Stock 19,635 3.00 58.9K 960,158 — ↗
2022-11-16 Zalevsky Jonathan Officer S-Sale D Common Stock 13,460 3.57 48.1K 313,663 — ↗
2022-11-16 Wilson Mark Andrew Officer S-Sale D Common Stock 8,690 3.57 31.0K 272,498 — ↗
2022-11-16 Thomsen Jillian B. Officer S-Sale D Common Stock 11,095 3.57 39.6K 323,764 — ↗
2022-11-16 ROBIN HOWARD W Officer S-Sale D Common Stock 38,014 3.57 135.7K 979,793 — ↗
2022-09-23 Curet Myriam Director S-Sale D Common Stock 4,198 3.16 13.3K 31,777 — ↗
2022-09-23 Ajer Jeffrey Robert Director S-Sale D Common Stock 4,198 3.16 13.3K 38,512 — ↗
2022-09-22 CHESS ROBERT Director S-Sale D Common Stock 5,100 3.19 16.3K 228,179 — ↗
2022-09-16 WHITFIELD ROY A Director A-Award A Stock Option 20,400 3.47 70.8K 20,400 — ↗
2022-09-16 EASTHAM KARIN Director A-Award A Stock Option 20,400 3.47 70.8K 20,400 — ↗
2022-09-16 Curet Myriam Director A-Award A Stock Option 20,400 3.47 70.8K 20,400 — ↗
2022-09-16 CHESS ROBERT Director A-Award A Stock Option 20,400 3.47 70.8K 20,400 — ↗
2022-09-16 Brainard Diana Director A-Award A Stock Option 20,400 3.47 70.8K 20,400 — ↗
2022-09-16 Ajer Jeffrey Robert Director A-Award A Stock Option 20,400 3.47 70.8K 20,400 — ↗
2022-09-13 EASTHAM KARIN Director S-Sale D Common Stock 21,267 3.61 76.8K 13,033 — ↗
2022-08-18 Zalevsky Jonathan Officer S-Sale D Common Stock 73,716 4.65 342.8K 327,123 — ↗
2022-08-15 Zalevsky Jonathan Officer A-Award A Common Stock 270,000 4.91 1.33M 270,000 — ↗
2022-08-15 Wilson Mark Andrew Officer S-Sale D Common Stock 3,189 4.76 15.2K 281,188 — ↗
2022-08-15 Thomsen Jillian B. Officer S-Sale D Common Stock 2,006 4.76 9.5K 334,859 — ↗
2022-08-15 ROBIN HOWARD W Director / Officer A-Award A Common Stock 821,250 4.91 4.03M 821,250 — ↗
2022-05-16 Wilson Mark Andrew Officer S-Sale D Common Stock 3,136 3.95 12.4K 117,939 — ↗
2022-05-16 NORTHCOTT JOHN Officer S-Sale D Common Stock 4,592 3.95 18.1K 223,210 — ↗
2022-05-15 Zalevsky Jonathan Officer S-Sale D Common Stock 21,673 3.95 85.6K 276,399 — ↗
2022-05-15 Thomsen Jillian B. Officer S-Sale D Common Stock 5,841 3.95 23.1K 170,427 — ↗
2022-05-15 ROBIN HOWARD W Officer S-Sale D Common Stock 36,529 3.95 144.3K 620,941 — ↗
2022-05-15 Labrucherie Gil M Officer S-Sale D Common Stock 17,448 3.95 68.9K 312,905 — ↗
2022-02-16 Zalevsky Jonathan Officer S-Sale D Common Stock 10,912 10.95 119.5K 274,122 — ↗
2022-02-16 Wilson Mark Andrew Officer S-Sale D Common Stock 3,661 10.95 40.1K 121,075 — ↗
2022-02-16 Thomsen Jillian B. Officer S-Sale D Common Stock 2,363 10.95 25.9K 165,318 — ↗
2022-02-16 ROBIN HOWARD W Director / Officer S-Sale D Common Stock 12,480 10.95 136.7K 589,020 — ↗
2022-02-16 NORTHCOTT JOHN Officer S-Sale D Common Stock 4,852 10.95 53.1K 227,802 — ↗
2022-02-16 Labrucherie Gil M Officer S-Sale D Common Stock 7,579 10.95 83.0K 301,603 — ↗
2021-12-16 Zalevsky Jonathan Officer A-Award A Stock Option 94,000 13.22 1.24M 94,000 — ↗
2021-12-16 Wilson Mark Andrew Officer A-Award A Stock Option 67,150 13.22 887.7K 67,150 — ↗
2021-12-16 Thomsen Jillian B. Officer A-Award A Stock Option 37,600 13.22 497.1K 37,600 — ↗
2021-12-16 ROBIN HOWARD W Director / Officer A-Award A Common Stock 126,050 0.00 — 601,500 — ↗
2021-12-16 NORTHCOTT JOHN Officer A-Award A Stock Option 67,150 13.22 887.7K 67,150 — ↗
2021-12-16 Labrucherie Gil M Officer A-Award A Stock Option 94,000 13.22 1.24M 94,000 — ↗
2021-11-18 Labrucherie Gil M Officer S-Sale D Common Stock 3,000 12.69 38.1K 256,682 — ↗
2021-11-16 Zalevsky Jonathan Officer S-Sale D Common Stock 20,869 13.16 274.6K 232,084 — ↗
2021-11-16 Wilson Mark Andrew Officer S-Sale D Common Stock 6,564 13.16 86.4K 86,436 — ↗
2021-11-16 Thomsen Jillian B. Officer S-Sale D Common Stock 6,741 13.16 88.7K 145,981 — ↗
2021-11-16 ROBIN HOWARD W Director / Officer S-Sale D Common Stock 42,773 13.16 562.9K 475,450 — ↗
2021-11-16 NORTHCOTT JOHN Officer S-Sale D Common Stock 6,061 13.16 79.8K 194,854 — ↗
2021-11-16 Labrucherie Gil M Officer S-Sale D Common Stock 21,149 13.16 278.3K 259,682 — ↗
2021-11-15 Zalevsky Jonathan Officer A-Award A Common Stock 40,150 0.00 — 252,953 — ↗
2021-11-15 Wilson Mark Andrew Officer A-Award A Common Stock 20,100 0.00 — 93,000 — ↗
2021-11-15 Thomsen Jillian B. Officer A-Award A Common Stock 14,900 0.00 — 152,722 — ↗
2021-11-15 ROBIN HOWARD W Director / Officer A-Award A Common Stock 94,100 0.00 — 518,223 — ↗
2021-11-15 Labrucherie Gil M Officer — — — 0 0.00 — 0 — ↗
2021-11-11 Brainard Diana Director A-Award A Common Stock 18,360 0.00 — 18,360 — ↗
2021-11-09 GREER R SCOTT Director M-Exempt A Common Stock 12,500 12.80 160.0K 293,374 — ↗
2021-10-12 Zalevsky Jonathan Officer A-Award A Stock Option 71,550 21.79 1.56M 71,550 — ↗
2021-10-12 Wilson Mark Andrew Officer A-Award A Stock Option 35,800 21.79 780.1K 35,800 — ↗
2021-10-12 Thomsen Jillian B. Officer A-Award A Stock Option 26,600 21.79 579.6K 26,600 — ↗
2021-10-12 ROBIN HOWARD W Director / Officer A-Award A Stock Option 167,650 21.79 3.65M 167,650 — ↗
2021-10-12 Labrucherie Gil M Officer A-Award A Stock Option 71,550 21.79 1.56M 71,550 — ↗
2021-09-22 WHITFIELD ROY A Director A-Award A Stock Option 20,400 17.78 362.7K 20,400 — ↗
2021-09-22 GREER R SCOTT Director A-Award A Stock Option 20,400 17.78 362.7K 20,400 — ↗
2021-09-22 EASTHAM KARIN Director A-Award A Common Stock 10,200 0.00 — 34,300 — ↗
2021-09-22 Curet Myriam Director S-Sale D Common Stock 3,665 17.78 65.2K 25,775 — ↗
2021-09-22 CHESS ROBERT Director A-Award A Stock Option 20,400 17.78 362.7K 20,400 — ↗
2021-09-22 Ajer Jeffrey Robert Director A-Award A Stock Option 20,400 17.78 362.7K 20,400 — ↗
2021-09-16 WHITFIELD ROY A Director M-Exempt A Common Stock 40,000 13.80 552.0K 225,850 — ↗
2021-09-09 CHESS ROBERT Director S-Sale D Common Stock 10,279 16.02 164.7K 274,273 — ↗
2021-09-08 CHESS ROBERT Director M-Exempt D Common Stock 8,000 13.80 110.4K 10,279 — ↗
2021-08-31 GREER R SCOTT Director M-Exempt A Common Stock 45,000 12.70 571.5K 270,674 — ↗
2021-08-24 CHESS ROBERT Director G-Gift D Common Stock 6,300 0.00 — 274,273 — ↗
2021-08-17 Labrucherie Gil M Officer S-Sale D Common Stock 3,000 13.56 40.7K 240,231 — ↗
2021-08-16 Zalevsky Jonathan Officer S-Sale D Common Stock 7,662 13.83 106.0K 212,803 — ↗
2021-08-16 Wilson Mark Andrew Officer S-Sale D Common Stock 1,910 13.83 26.4K 72,900 — ↗
2021-08-16 Thomsen Jillian B. Officer S-Sale D Common Stock 13,339 13.83 184.5K 137,822 — ↗
2021-08-16 ROBIN HOWARD W Director / Officer S-Sale D Common Stock 11,515 13.83 159.3K 424,123 — ↗
2021-08-16 NORTHCOTT JOHN Officer S-Sale D Common Stock 6,192 13.83 85.6K 200,915 — ↗
2021-08-16 Labrucherie Gil M Officer S-Sale D Common Stock 7,867 13.83 108.8K 243,231 — ↗
2021-07-22 CHESS ROBERT Director M-Exempt A Common Stock 91 13.80 1.3K 280,664 — ↗
2021-07-21 CHESS ROBERT Director M-Exempt A Common Stock 3,524 13.80 48.6K 284,097 — ↗
2021-07-20 CHESS ROBERT Director M-Exempt A Common Stock 2,106 13.80 29.1K 282,679 — ↗
2021-05-17 Zalevsky Jonathan Officer S-Sale D Common Stock 31,111 18.30 569.3K 235,065 — ↗
2021-05-17 Wilson Mark Andrew Officer S-Sale D Common Stock 1,917 18.30 35.1K 74,810 — ↗
2021-05-17 Thomsen Jillian B. Officer S-Sale D Common Stock 13,391 18.30 245.1K 151,161 — ↗
2021-05-17 ROBIN HOWARD W Director / Officer S-Sale D Common Stock 11,560 18.30 211.5K 435,638 — ↗
2021-05-17 NORTHCOTT JOHN Officer S-Sale D Common Stock 6,085 18.30 111.4K 207,107 — ↗
2021-05-17 Labrucherie Gil M Officer S-Sale D Common Stock 7,898 18.30 144.5K 251,098 — ↗
2021-05-12 CHESS ROBERT Director M-Exempt A Common Stock 8,000 13.80 110.4K 288,573 — ↗
2021-04-14 CHESS ROBERT Director S-Sale D Common Stock 8,000 18.98 151.8K 280,573 — ↗
2021-02-16 Zalevsky Jonathan Officer S-Sale D Common Stock 24,141 22.37 540.0K 266,176 — ↗
2021-02-16 Wilson Mark Andrew Officer S-Sale D Common Stock 2,173 22.37 48.6K 76,727 — ↗
2021-02-16 Thomsen Jillian B. Officer S-Sale D Common Stock 11,705 22.37 261.8K 164,552 — ↗
2021-02-16 ROBIN HOWARD W Director / Officer S-Sale D Common Stock 11,495 22.37 257.1K 447,198 — ↗
2021-02-16 NORTHCOTT JOHN Officer S-Sale D Common Stock 15,358 22.37 343.6K 213,192 — ↗
2021-02-16 Labrucherie Gil M Officer S-Sale D Common Stock 7,977 22.37 178.4K 258,996 — ↗
2021-02-04 ROBIN HOWARD W Director / Officer M-Exempt A Common Stock 150,000 8.80 1.32M 608,693 — ↗
2021-02-04 Labrucherie Gil M Officer S-Sale D Common Stock 50,000 19.81 990.5K 266,973 — ↗
2021-02-03 Wilson Mark Andrew Officer M-Exempt D Stock Option 5,344 8.80 47.0K 0 — ↗
2021-02-03 ROBIN HOWARD W Director / Officer M-Exempt D Stock Option 75,000 8.80 660.0K 150,000 — ↗
2021-02-03 Labrucherie Gil M Officer M-Exempt A Common Stock 25,000 8.80 220.0K 291,973 — ↗
2021-02-02 ROBIN HOWARD W Director / Officer S-Sale D Common Stock 600 21.59 13.0K 458,693 — ↗
2021-02-02 Labrucherie Gil M Officer M-Exempt D Stock Option 50,000 8.80 440.0K 25,000 — ↗
2021-01-28 Thomsen Jillian B. Officer M-Exempt A Common Stock 37,500 8.80 330.0K 213,757 — ↗
2021-01-05 GREER R SCOTT Director M-Exempt A Common Stock 40,000 13.80 552.0K 225,674 — ↗
2020-12-30 WHITFIELD ROY A Director G-Gift D Common Stock 51,500 0.00 — 185,850 — ↗
2020-12-18 Zalevsky Jonathan Officer A-Award A Common Stock 40,000 0.00 — 290,317 — ↗
2020-12-18 Wilson Mark Andrew Officer A-Award A Stock Option 51,000 18.75 956.3K 51,000 — ↗
2020-12-18 Thomsen Jillian B. Officer A-Award A Stock Option 28,600 18.75 536.3K 28,600 — ↗
2020-12-18 ROBIN HOWARD W Director / Officer A-Award A Common Stock 106,650 0.00 — 458,693 — ↗
2020-12-18 NORTHCOTT JOHN Officer A-Award A Stock Option 51,000 18.75 956.3K 51,000 — ↗
2020-12-18 Labrucherie Gil M Officer A-Award A Stock Option 71,500 18.75 1.34M 71,500 — ↗
2020-12-15 Myriam Curet Director S-Sale D Common Stock 1,560 17.82 27.8K 19,240 — ↗
2020-11-23 Zalevsky Jonathan Officer S-Sale D Common Stock 16,380 16.40 268.6K 250,317 — ↗
2020-11-16 Zalevsky Jonathan Officer S-Sale D Common Stock 29,618 16.93 501.4K 266,697 — ↗
2020-11-16 Wilson Mark Andrew Officer S-Sale D Common Stock 1,539 16.93 26.1K 49,850 — ↗
2020-11-16 Thomsen Jillian B. Officer S-Sale D Common Stock 11,976 16.93 202.8K 159,757 — ↗
2020-11-16 ROBIN HOWARD W Director / Officer S-Sale D Common Stock 11,975 16.93 202.7K 352,043 — ↗
2020-11-16 Labrucherie Gil M Officer S-Sale D Common Stock 8,276 16.93 140.1K 226,973 — ↗
2020-09-28 Ajer Jeffrey Robert Director S-Sale D Common Stock 3,250 17.25 56.1K 25,975 — ↗

Executive team

Top executives
EBIT / Employee
-21.4K
Shares Outstanding
20.30M

Executive compensation

Executive compensation (annual)
# Year ⇅ Executive ⇅ Salary ⇅ Bonus Stock award ⇅ Option award Incentive Other Total ⇅ % Stock-
based ⇅		 Filing
1 2025 Howard W. Robin President and Chief Executive Officer 1.11M — 942.1K 2.99M 1.11M 115.8K 6.26M 62.79% ↗
2 2025 Jonathan Zalevsky, Ph.D. Chief Research and Development Officer 717.6K — 271.8K 861.5K 452.0K 17.6K 2.32M 48.84% ↗
3 2025 Sandra Gardiner Interim Chief Financial Officer — — — — — 686.4K 686.4K 0.00% ↗
4 2025 Mark A. Wilson Former Chief Legal Officer 646.0K — — — — 22.0K 667.9K 0.00% ↗
5 2024 Howard W. Robin President and Chief Executive Officer 1.08M — — 1.60M 976.1K 105.9K 3.76M 42.42% ↗
6 2024 Jonathan Zalevsky, Ph.D. Chief Research and Development Officer 703.5K — — 460.4K 431.9K 15.8K 1.61M 28.57% ↗
7 2024 Mark A. Wilson Former Chief Legal Officer 540.0K — — 399.0K 336.6K 21.7K 1.30M 30.76% ↗
8 2024 Mark A. Wilson Chief Legal Officer 540.0K — — 399.0K 336.6K 21.7K 1.30M 30.76% ↗
9 2024 Sandra Gardiner Interim Chief Financial Officer — — — — — 460.9K 460.9K 0.00% ↗
10 2023 Howard W. Robin President and Chief Executive Officer 1.08M — — 927.2K 1.03M 93.5K 3.14M 29.57% ↗
11 2023 Jonathan Zalevsky, Ph.D. Chief Research and Development Officer 703.5K — — 178.3K 401.0K 490.6K 1.77M 10.05% ↗
12 2023 Jillian B. Thomsen Former Chief Financial Officer and Chief Accounting Officer 355.8K — — — — 884.0K 1.24M 0.00% ↗
13 2023 Mark A. Wilson Chief Legal Officer 540.0K — — 231.8K 307.8K 20.9K 1.10M 21.06% ↗
14 2023 Mark A. Wilson Former Chief Legal Officer 540.0K — — 231.8K 307.8K 20.9K 1.10M 21.06% ↗
15 2023 Sandra Gardiner Interim Chief Financial Officer — — — — — 376.3K 376.3K 0.00% ↗
16 2022 Howard W. Robin President and Chief Executive Officer 1.08M — 4.03M 5.41M 650.8K 98.8K 11.28M 83.73% ↗
17 2022 Mark A. Wilson Chief Legal Officer 527.5K — 1.63M 2.19M 194.4K 28.1K 4.57M 83.57% ↗
18 2022 Jillian B. Thomsen Former Chief Financial Officer and Chief Accounting Officer 522.2K — 1.63M 2.19M 198.0K 22.6K 4.56M 83.70% ↗
19 2022 Jonathan Zalevsky, Ph.D. Chief Research and Development Officer 703.5K — 1.33M 1.78M 253.3K 289.6K 4.35M 71.35% ↗
20 2022 John Northcott Former Chief Commercial Officer 441.7K — — — — 923.0K 1.36M 0.00% ↗
21 2022 Gil M. Labrucherie Former Chief Operating Officer and Chief Financial Officer 576.7K — — — — 11.0K 587.7K 0.00% ↗
22 2022 Jillian B. Thomsen Chief Financial Officer and Chief Accounting Officer 522.2K — 1.63M 2.19M 198.0K 22.6K 58.3K 6,542.64% ↗
23 2021 Howard W. Robin President and Chief Executive Officer 1.05M — 5.69M 3.33M 1.00M 82.0K 11.15M 80.86% ↗
24 2021 Gil M. Labrucherie Former Chief Operating Officer and Chief Financial Officer 788.0K — 2.39M 1.40M 679.7K 23.3K 5.28M 71.76% ↗
25 2021 Gil M. Labrucherie Chief Operating Officer and Chief Financial Officer 788.0K — 2.39M 1.40M 679.7K 23.3K 5.28M 71.76% ↗
26 2021 Jonathan Zalevsky, Ph.D. Chief Research and Development Officer 683.0K — 2.39M 1.40M 471.3K 8.4K 4.95M 76.52% ↗
27 2021 Jonathan Zalevsky, Ph.D. Senior Vice President and Chief Research and Development Officer 683.0K — 2.39M 1.40M 471.3K 8.4K 4.95M 76.52% ↗
28 2021 John Northcott Senior Vice President and Chief Commercial Officer 675.0K — 1.71M 998.3K 388.1K 8.0K 3.78M 71.64% ↗
29 2021 John Northcott Former Chief Commercial Officer 675.0K — 1.71M 998.3K 388.1K 8.0K 3.78M 71.64% ↗
30 2021 Mark A. Wilson Senior Vice President and General Counsel 500.0K — 1.71M 998.3K 287.5K 10.8K 3.50M 77.22% ↗
31 2021 Mark A. Wilson Chief Legal Officer 500.0K — 1.71M 998.3K 287.5K 10.8K 3.50M 77.22% ↗
32 2020 Howard W. Robin President and Chief Executive Officer 1.05M — 5.00M 4.00M 1.09M 95.8K 11.24M 80.07% ↗
33 2020 Gil M. Labrucherie Former Chief Operating Officer and Chief Financial Officer 788.0K — 2.25M 1.50M 721.0K 27.6K 5.29M 70.93% ↗
34 2020 Gil M. Labrucherie Chief Operating Officer and Chief Financial Officer 788.0K — 2.25M 1.50M 721.0K 27.6K 5.29M 70.93% ↗
35 2020 Jonathan Zalevsky, Ph.D. Chief Research and Development Officer 683.0K — 2.25M 1.50M 500.0K 9.1K 4.94M 75.87% ↗
36 2020 Jonathan Zalevsky, Ph.D. Senior Vice President and Chief Research and Development Officer 683.0K — 2.25M 1.50M 500.0K 9.1K 4.94M 75.87% ↗
37 2020 John Northcott Former Chief Commercial Officer 675.0K — 1.60M 1.07M 364.5K 117.9K 3.83M 69.80% ↗
38 2020 John Northcott Senior Vice President and Chief Commercial Officer 675.0K — 1.60M 1.07M 364.5K 117.9K 3.83M 69.80% ↗
39 2020 Mark A. Wilson Senior Vice President and General Counsel 500.0K — 1.60M 1.07M 270.0K 10.5K 3.46M 77.42% ↗
40 2020 Mark A. Wilson Chief Legal Officer 500.0K — 1.60M 1.07M 270.0K 10.5K 3.46M 77.42% ↗
41 2019 Howard W. Robin President and Chief Executive Officer 1.02M — 4.10M 4.65M — 168.9K 9.94M 88.06% ↗
42 2019 Gil M. Labrucherie Chief Operating Officer and Chief Financial Officer 683.3K — 3.13M 3.66M — 12.5K 7.49M 90.71% ↗
43 2019 Jonathan Zalevsky, Ph.D. Chief Research and Development Officer 582.0K — 3.13M 3.55M — 8.1K 7.27M 91.89% ↗
44 2019 Jonathan Zalevsky, Ph.D. Senior Vice President and Chief Research and Development Officer 582.0K — 3.13M 3.55M — 8.1K 7.27M 91.89% ↗
45 2019 John Northcott Senior Vice President and Chief Commercial Officer 56.3K 200.0K 3.90M 2.19M — 23.3K 6.37M 95.61% ↗
46 2019 Jillian B. Thomsen Senior Vice President Finance and Chief Accounting Officer 457.0K — 649.3K 796.0K — 13.8K 1.92M 75.43% ↗
47 2018 Howard W. Robin President and Chief Executive Officer 968.9K — 5.00M 5.62M 1.65M 98.2K 13.33M 79.64% ↗
48 2018 Jillian B. Thomsen Senior Vice President Finance and Chief Accounting Officer 435.0K — 4.46M 899.5K 424.1K 13.3K 6.23M 86.00% ↗
49 2018 Gil M. Labrucherie Chief Operating Officer and Chief Financial Officer 631.7K — 2.10M 2.36M 631.6K 11.9K 5.73M 77.76% ↗
50 2018 Gil M. Labrucherie Senior Vice President and Chief Financial Officer 631.7K — 2.10M 2.36M 631.6K 11.9K 5.73M 77.76% ↗
51 2018 Stephen K. Doberstein, Ph.D. Chief Research and Development Officer 600.0K — 1.75M 1.97M 480.0K 17.6K 4.81M 77.19% ↗
52 2018 Maninder Hora, Ph.D. Senior Vice President Pharmaceutical Development and Chief Technical Operations Officer 489.4K — 1.35M 1.52M 464.9K 17.5K 3.84M 74.69% ↗
53 2017 Howard W. Robin President and Chief Executive Officer 940.7K — 6.88M 8.54M 1.60M 128.0K 18.10M 85.26% ↗
54 2017 John Nicholson Senior Vice President and Chief Operating Officer 625.8K — 2.96M 3.67M 547.6K 26.9K 7.83M 84.67% ↗
55 2017 Gil M. Labrucherie Chief Operating Officer and Chief Financial Officer 607.4K — 2.96M 3.67M 531.5K 10.3K 7.78M 85.23% ↗
56 2017 Gil M. Labrucherie Senior Vice President and Chief Financial Officer 607.4K — 2.96M 3.67M 531.5K 10.3K 7.78M 85.23% ↗
57 2017 Stephen K. Doberstein, Ph.D. Senior Vice President and Chief Research and Development Officer 529.1K — 2.96M 3.67M 525.0K 14.0K 7.70M 86.13% ↗
58 2017 Stephen K. Doberstein, Ph.D. Chief Research and Development Officer 529.1K — 2.96M 3.67M 525.0K 14.0K 7.70M 86.13% ↗
59 2017 Maninder Hora, Ph.D. Senior Vice President Pharmaceutical Development and Chief Technical Operations Officer 471.5K — 1.71M 2.12M 353.6K 15.4K 4.67M 81.99% ↗
60 2016 Howard W. Robin President and Chief Executive Officer 920.0K — 1.35M 1.59M 897.0K 15.1K 4.76M 61.54% ↗
61 2016 John Nicholson Senior Vice President and Chief Operating Officer 599.8K — 489.6K 1.30M 367.2K 15.0K 2.77M 64.61% ↗
62 2016 Gil M. Labrucherie Senior Vice President and Chief Financial Officer 582.2K — 489.6K 1.30M 356.4K 8.7K 2.74M 65.43% ↗
63 2016 Ivan P. Gergel , M.D. Senior Vice President and Chief Medical Officer 639.6K — 489.6K 1.14M 335.8K 9.8K 2.62M 62.37% ↗
64 2016 Stephen K. Doberstein, Ph.D. Senior Vice President and Chief Scientific Officer 508.2K — 428.4K 504.5K 266.8K 12.8K 1.72M 54.22% ↗
65 2016 Stephen K. Doberstein, Ph.D. Chief Research and Development Officer 508.2K — 428.4K 504.5K 266.8K 12.8K 1.72M 54.22% ↗
66 2016 Stephen K. Doberstein, Ph.D. Senior Vice President and Chief Research and Development Officer 508.2K — 428.4K 504.5K 266.8K 12.8K 1.72M 54.22% ↗
67 2016 Maninder Hora, Ph.D. Senior Vice President Pharmaceutical Development and Manufacturing Operations 447.8K — 367.2K 432.5K 279.9K 14.5K 1.54M 51.87% ↗
68 2016 Maninder Hora, Ph.D. Senior Vice President Pharmaceutical Development and Chief Technical Operations Officer 447.8K — 367.2K 432.5K 279.9K 14.5K 1.54M 51.87% ↗
69 2015 Howard W. Robin President and Chief Executive Officer 892.6K — 2.10M 817.0K 625.0K 12.2K 4.45M 65.59% ↗
70 2015 John Nicholson Senior Vice President and Chief Financial Officer 563.1K — 808.6K 319.5K 267.5K 12.7K 1.97M 57.22% ↗
71 2015 John Nicholson Senior Vice President and Chief Operating Officer 563.1K — 808.6K 319.5K 267.5K 12.7K 1.97M 57.22% ↗
72 2015 Gil M. Labrucherie Senior Vice President and General Counsel 546.5K — 808.6K 319.5K 259.6K 9.6K 1.94M 58.04% ↗
73 2015 Gil M. Labrucherie Senior Vice President and Chief Financial Officer 546.5K — 808.6K 319.5K 259.6K 9.6K 1.94M 58.04% ↗
74 2015 Maninder Hora, Ph.D. Senior Vice President Pharmaceutical Development and Manufacturing Operations 430.6K — 808.6K 319.5K 204.5K 14.8K 1.78M 63.45% ↗
75 2015 Maninder Hora, Ph.D. Senior Vice President Pharmaceutical Development and Chief Technical Operations Officer 430.6K — 808.6K 319.5K 204.5K 14.8K 1.78M 63.45% ↗
76 2015 Maninder Hora Senior Vice President Pharmaceutical Development and Manufacturing Operations 430.6K — 808.6K 319.5K 204.5K 14.8K 1.78M 63.45% ↗
77 2015 Ivan P. Gergel , M.D. Senior Vice President and Chief Medical Officer 621.0K — 466.5K 181.6K 279.5K 6.7K 1.56M 41.67% ↗
78 2015 Ivan P. Gergel Senior Vice President and Chief Medical Officer 621.0K — 466.5K 181.6K 279.5K 6.7K 1.56M 41.67% ↗
79 2015 Stephen K. Doberstein, Ph.D. Senior Vice President and Chief Research and Development Officer 495.8K — 326.5K 127.1K 198.3K 13.1K 1.16M 39.06% ↗
80 2015 Stephen K. Doberstein, Ph.D. Senior Vice President and Chief Scientific Officer 495.8K — 326.5K 127.1K 198.3K 13.1K 1.16M 39.06% ↗
81 2014 Howard W. Robin President and Chief Executive Officer 860.0K — — 6.02M 1.13M 18.3K 8.03M 74.98% ↗
82 2014 Howard W. Robin President and Chief Executive Officer 860.0K — — 6.02M 1.13M 18.3K 8.03M 74.98% ↗
83 2014 Ivan P. Gergel , M.D. Senior Vice President and Chief Medical Officer 372.7K — — 3.61M 227.5K 2.1K 4.21M 85.70% ↗
84 2014 Ivan P. Gergel Senior Vice President and Chief Medical Officer 8.00 — — 3.61M 227.5K 2.1K 4.21M 85.70% ↗
85 2014 John Nicholson Senior Vice President and Chief Operating Officer 542.5K — — 2.34M 408.0K 12.9K 3.31M 70.86% ↗
86 2014 John Nicholson Senior Vice President and Chief Financial Officer 542.5K — — 2.34M 408.0K 12.9K 3.31M 70.86% ↗
87 2014 John Nicholson Senior Vice President and Chief Financial Officer 8.00 — — 2.34M 408.0K 12.9K 3.31M 70.86% ↗
88 2014 Gil M. Labrucherie Senior Vice President and General Counsel 526.1K — — 2.31M 396.0K 8.4K 3.24M 71.31% ↗
89 2014 Gil M. Labrucherie Senior Vice President and Chief Financial Officer 526.1K — — 2.31M 396.0K 8.4K 3.24M 71.31% ↗
90 2014 Gil M. Labrucherie Senior Vice President and General Counsel 5.00 — — 2.31M 396.0K 8.4K 3.24M 71.31% ↗
91 2014 Stephen K. Doberstein, Ph.D. Senior Vice President and Chief Scientific Officer 477.6K — — 1.34M 311.4K 11.8K 2.14M 62.57% ↗
92 2014 Stephen K. Doberstein Senior Vice President and Chief Scientific Officer 477.6K — — 1.34M 311.4K 11.8K 2.14M 62.57% ↗
93 2013 Howard W. Robin President and Chief Executive Officer 7.00 — — 2.07M 656.2K 15.0K 3.57M 57.91% ↗
94 2013 Howard W. Robin President and Chief Executive Officer 831.2K — — 2.07M 656.2K 15.0K 3.57M 57.91% ↗
95 2013 John Nicholson Senior Vice President and Chief Financial Officer 4.00 — — 849.8K 276.0K 12.1K 1.66M 51.13% ↗
96 2013 John Nicholson Senior Vice President and Chief Financial Officer 524.3K — — 849.8K 276.0K 12.1K 1.66M 51.13% ↗
97 2013 Gil M. Labrucherie Senior Vice President and General Counsel 504.2K — — 689.1K 278.0K 7.2K 1.48M 46.61% ↗
98 2013 Gil M. Labrucherie Senior Vice President and General Counsel 5.00 — — 689.1K 278.0K 7.2K 1.48M 46.61% ↗
99 2013 Stephen K. Doberstein Senior Vice President and Chief Scientific Officer 459.7K — — 459.4K 231.0K 9.5K 1.16M 39.61% ↗
100 2013 Name and Position — — — — — — — — ↗
101 2012 Howard W. Robin President and Chief Executive Officer 807.2K 500.00 — 1.51M 910.1K 14.4K 3.24M 46.58% ↗
102 2012 Gil M. Labrucherie Senior Vice President and General Counsel 488.3K — — 566.3K 330.0K 6.5K 1.39M 40.71% ↗
103 2012 John Nicholson Senior Vice President and Chief Financial Officer 509.5K 500.00 — 377.5K 357.0K 12.2K 1.26M 30.04% ↗
104 2012 Stephen K. Doberstein Senior Vice President and Chief Scientific Officer 433.6K — — 377.5K 260.0K 9.6K 1.08M 34.93% ↗
105 2011 Howard W. Robin President and Chief Executive Officer 785.1K — — 1.73M 650.0K 15.0K 3.18M 54.44% ↗
106 2010 Howard W. Robin President and Chief Executive Officer 758.6K — — 3.02M 700.0K 15.0K 4.49M 67.20% ↗
107 2010 Stephen K. Doberstein Ph.D. Senior Vice President and Chief Scientific Officer 395.5K 150.0K — — 240.0K 7.8K 3.53M 0.00% ↗
108 2010 Rinko Ghosh Senior Vice President and Chief Business Officer 397.7K — — — 276.8K 8.0K 2.22M 0.00% ↗
109 2010 John Nicholson Senior Vice President, Finance and Chief Financial Officer 478.4K — — — 288.0K 15.3K 1.51M 0.00% ↗
110 2010 Gil M. Labrucherie Senior Vice President and General Counsel 434.3K 500.00 — — 294.3K 13.3K 1.47M 0.00% ↗
111 2009 Howard W. Robin President and Chief Executive Officer 730.4K — — — 1.00M 15.0K 3.00M 0.00% ↗
112 2009 John Nicholson Senior Vice President, Finance and Chief Financial Officer 459.6K — — — 403.5K 51.2K 1.84M 0.00% ↗
113 2009 Gil M. Labrucherie Senior Vice President and General Counsel 412.2K — — — 363.5K 13.1K 1.80M 0.00% ↗
114 2009 Name and Position — — — — — — — — ↗
115 2008 Howard W. Robin President and Chief Executive Officer 680.0K — — — 618.8K 14.6K 2.51M 0.00% ↗
116 2008 Nevan C. Elam Senior Vice President and Head of the Pulmonary Business Unit 438.7K 250.0K — — — 653.7K 1.95M 0.00% ↗
117 2008 John Nicholson Senior Vice President, Finance and Chief Financial Officer 442.5K — — — 388.6K 108.6K 1.19M 0.00% ↗
118 2008 Gil M. Labrucherie Senior Vice President and General Counsel 380.1K 100.0K 10.7K — 381.9K 9.4K 1.18M 0.91% ↗
119 2008 Gil M. Labrucherie Senior Vice President and General Counsel 380.1K 100.0K — — 381.9K 9.4K 1.08M 0.00% ↗
120 2008 Bharatt M. Chowrira 295.1K 80.5K — — 427.5K 4.4K 951.2K 0.00% ↗
121 2007 Howard W. Robin President and Chief Executive Officer 654.2K — — — 601.8K 4.1K 2.23M 0.00% ↗
122 2007 Howard W. Robin President and Chief Executive Officer 654.2K — — — 601.8K 4.1K 2.23M 0.00% ↗
123 2007 Robert B. Chess Former Acting President and Chief Executive Officer 100.0K 317.0K 339.8K — — 8.7K 1.47M 23.13% ↗
124 2007 Hoyoung Huh M.D., Ph.D. Chief Operating Officer and Head of the PEGylation Business Unit 451.2K 20.0K — — 344.0K 9.2K 1.23M 0.00% ↗
125 2007 David Johnston Former Senior Vice President Research and Development 390.8K 42.0K 18.3K — 71.2K 528.9K 1.18M 1.55% ↗
126 2007 Timothy Harkness Former Senior Vice President, Finance and Chief Financial Officer 141.1K — 6.6K — — 739.4K 937.2K 0.70% ↗
127 2007 Nevan C. Elam Senior Vice President and Head of the Pulmonary Business Unit 372.6K — — — 282.8K 2.9K 933.1K 0.00% ↗
128 2007 Nevan C. Elam Senior Vice President and Head of the Pulmonary Business Unit 372.6K — — — 282.8K 2.9K 933.1K 0.00% ↗
129 2007 Louis Drapeau Former Senior Vice President, Finance and Chief Financial Officer 252.4K — — — 64.8K 404.4K 881.4K 0.00% ↗
130 2007 John S. Patton, Ph.D. Chief Research Fellow 303.2K 86.3K 70.9K — 164.5K 33.8K 833.2K 8.51% ↗
131 2007 John Nicholson Senior Vice President, Finance and Chief Financial Officer 104.6K — 1.1K — 82.3K 31.2K 273.5K 0.39% ↗
132 2007 John Nicholson Senior Vice President, Finance and Chief Financial Officer 104.6K — 1.1K — 82.3K 31.2K 273.5K 0.39% ↗
133 2006 Ajit S. Gill President and Chief Executive Officer 285.4K — 1.39M 8.79M 149.0K 1.70M 12.31M 82.66% ↗
134 2006 Robert B. Chess Former Acting President and Chief Executive Officer 418.5K — 716.2K — 262.7K 8.0K 2.42M 29.63% ↗
135 2006 Robert B. Chess Acting President and Chief Executive Officer 418.5K — 716.2K 1.01M 262.7K 8.0K 2.42M 71.49% ↗
136 2006 Ajay Bansal Senior Vice President of Finance and Chief Financial Officer 74.1K — 349.1K 346.6K 25.0K 457.3K 1.25M 55.56% ↗
137 2006 John S. Patton, Ph.D. Chief Scientific Officer 286.5K — 292.3K 103.4K 131.1K 9.1K 822.4K 48.12% ↗
138 2006 John S. Patton, Ph.D. Chief Research Fellow 286.5K — 292.3K — 131.1K 9.1K 822.4K 35.54% ↗
139 2006 David Johnston Former Senior Vice President Research and Development 335.9K — 71.2K — 119.6K 9.8K 701.9K 10.14% ↗
140 2006 David Johnston Senior Vice President Research and Development 335.9K — 71.2K 165.5K 119.6K 9.8K 701.9K 33.72% ↗
141 2006 Louis Drapeau Senior Vice President, Finance and Chief Financial Officer 336.6K — — 201.5K 120.0K 11.4K 669.4K 30.10% ↗
142 2006 Louis Drapeau Former Senior Vice President, Finance and Chief Financial Officer 336.6K — — — 120.0K 11.4K 669.4K 0.00% ↗
143 2006 Nevan C. Elam Senior Vice President and Head of the Pulmonary Business Unit 321.3K — 35.9K — 114.8K 582.00 649.6K 5.53% ↗
144 2006 Nevan C. Elam Senior Vice President and Head of the Pulmonary Business Unit 321.3K — 35.9K — 114.8K 582.00 649.6K 5.53% ↗
145 2005 Ajit S. Gill Chief Executive Officer, President and Director 510.8K 262.8K 904.0K 125.0K — 11.1K 1.69M 60.93% ↗
146 2005 David Johnston Senior Vice President Research Development 314.2K 129.3K 184.5K 20.0K — 9.3K 637.3K 32.09% ↗
147 2005 Ajay Bansal Chief Financial Officer 307.8K 122.8K 185.4K 20.0K — 3.8K 619.9K 33.14% ↗
148 2005 John S. Patton, Ph.D. Founder, Chief Scientific Officer and Director 274.6K 142.7K 184.5K 20.0K — 7.8K 609.6K 33.55% ↗
149 2005 Robert B. Chess Executive Chairman 135.8K 80.9K — 25.0K — 8.4K 225.1K 11.11% ↗
150 2004 Ajit S. Gill Chief Executive Officer, President and Director 498.0K 272.3K 977.5K 100.0K — 10.3K 1.76M 61.29% ↗
151 2004 Ajay Bansal Chief Financial Officer 288.7K 105.2K 476.3K — — 7.0K 877.1K 54.30% ↗
152 2004 John S. Patton, Ph.D. Founder, Chief Scientific Officer and Director 261.4K 127.1K 476.3K — — 6.7K 871.4K 54.65% ↗
153 2004 Robert B. Chess Executive Chairman 167.0K 93.6K 325.8K 33.3K — 7.4K 593.9K 60.48% ↗
154 2004 J. Milton Harris, Ph.D. Chief Scientific Officer, Nektar Therapeutics AL, Corporation 342.4K 153.6K — 10.0K — 11.1K 507.1K 1.97% ↗
155 2004 David Johnston Senior Vice President Research Development 300.0K 83.5K — 50.0K — 7.5K 391.0K 12.79% ↗
156 2003 Ajit S. Gill Chief Executive Officer, President and Director 474.5K 250.9K — 150.0K — 10.0K 735.3K 20.40% ↗
157 2003 J. Milton Harris, Ph.D. President, Nektar Therapeutics AL, Corporation 321.0K 110.7K — 35.0K — 8.0K 439.6K 7.96% ↗
158 2003 J. Milton Harris, Ph.D. Chief Scientific Officer, Nektar Therapeutics AL, Corporation 321.0K 110.7K — 35.0K — 8.0K 439.6K 7.96% ↗
159 2003 Ajay Bansal Chief Financial Officer 235.3K 170.1K — 90.0K — 4.7K 410.1K 21.95% ↗
160 2003 John S. Patton, Ph.D. Founder, Chief Scientific Officer and Director 248.9K 112.8K — 30.0K — 8.3K 370.0K 8.11% ↗
161 2003 Robert B. Chess Executive Chairman 183.6K 115.3K — 52.5K — 6.6K 305.5K 17.18% ↗
162 2003 David Johnston Senior Vice President Research Development — — — — — — — — ↗
163 2002 Ajit S. Gill Chief Executive Officer, President and Director 451.2K 201.4K — 150.0K — 7.2K 659.8K 22.73% ↗
164 2002 J. Milton Harris, Ph.D. Chief Scientific Officer, Nektar Therapeutics AL, Corporation 324.0K 187.0K — 39.0K — 7.5K 518.5K 7.52% ↗
165 2002 J. Milton Harris, Ph.D. President, Nektar Therapeutics AL, Corporation 324.0K 187.0K — 39.0K — 7.5K 518.5K 7.52% ↗
166 2002 Arnold J. Repta, Ph.D. Vice President, Research and Development 373.1K 71.5K — 100.0K — 9.1K 453.6K 22.05% ↗
167 2002 Douglas H. Altschuler Former Vice President, General Counsel and Secretary 307.5K 68.4K — — — 6.7K 382.6K 0.00% ↗
168 2002 Robert B. Chess Executive Chairman 251.7K 117.2K — 75.0K — 6.6K 375.5K 19.97% ↗
169 2002 John S. Patton, Ph.D. Founder, Chief Scientific Officer and Director 236.8K 90.9K — 14.0K — 7.9K 335.6K 4.17% ↗
170 2002 David Johnston Senior Vice President Research Development — — — — — — — — ↗
171 2002 Ajay Bansal Chief Financial Officer — — — — — — — — ↗
172 2001 Ajit S. Gill Chief Executive Officer, President and Director 422.1K 201.1K — 370.0K — 6.1K 629.3K 58.80% ↗
173 2001 Robert B. Chess Executive Chairman 254.1K 121.3K — 222.0K — 5.5K 380.9K 58.28% ↗
174 2001 John S. Patton, Ph.D. Founder, Chief Scientific Officer and Director 222.8K 90.1K — 14.0K — 6.9K 319.9K 4.38% ↗
175 2001 John S. Patton Founder, Chief Scientific Officer and Director 222.8K 90.1K — 14.0K — 6.9K 319.9K 4.38% ↗
176 2001 Brigid A. Makes Vice President, Finance Administration, Chief Financial Officer and Assistant Secretary 219.3K 68.9K — 49.8K — 5.7K 294.0K 16.94% ↗
177 2001 Stephen L. Hurst Vice President, Human Resources 129.1K 54.2K — 7.0K — 4.5K 187.8K 3.73% ↗
178 2001 J. Milton Harris, Ph.D. President, Nektar Therapeutics AL, Corporation 156.0K — — 100.0K — 450.00 156.5K 63.92% ↗
179 2001 Douglas H. Altschuler Vice President, General Counsel and Secretary 61.9K 25.0K — 100.0K — 158.00 87.1K 114.87% ↗
180 2001 Douglas H. Altschuler Former Vice President, General Counsel and Secretary 61.9K 25.0K — 100.0K — 158.00 87.1K 114.87% ↗
181 2001 Arnold J. Repta, Ph.D. Vice President, Research and Development — — — — — — — — ↗
182 2001 Ajay Bansal Chief Financial Officer — — — — — — — — ↗
183 2000 Ajit S. Gill Chief Executive Officer, President and Director 387.8K 746.5K — 350.0K — 6.1K 1.14M 30.69% ↗
184 2000 Robert B. Chess Executive Chairman 251.3K 668.9K — 326.7K — 5.5K 925.7K 35.29% ↗
185 2000 John S. Patton Founder, Chief Scientific Officer and Director 209.3K 92.4K — 19.6K — 1.7K 303.3K 6.46% ↗
186 2000 John S. Patton, Ph.D. Founder, Chief Scientific Officer and Director 209.3K 92.4K — 19.6K — 1.7K 303.3K 6.46% ↗
187 2000 Brigid A. Makes Vice President, Finance Administration, Chief Financial Officer and Assistant Secretary 205.8K 70.6K — 19.6K — 5.7K 282.1K 6.95% ↗
188 2000 Stephen L. Hurst Vice President, Human Resources 171.9K 96.0K — 79.6K — 3.4K 271.3K 29.34% ↗
189 2000 Douglas H. Altschuler Vice President, General Counsel and Secretary — — — — — — — — ↗
190 2000 Douglas H. Altschuler Former Vice President, General Counsel and Secretary — — — — — — — — ↗
191 2000 Arnold J. Repta, Ph.D. Vice President, Research and Development — — — — — — — — ↗
192 2000 J. Milton Harris, Ph.D. President, Nektar Therapeutics AL, Corporation — — — — — — — — ↗
193 1999 Ajit S. Gill Chief Executive Officer, President and Director 248.0K 113.2K — 100.0K — 6.5K 367.7K 27.20% ↗
194 1999 Robert B. Chess Executive Chairman 248.0K 113.2K — 100.0K — 6.0K 367.3K 27.23% ↗
195 1999 John S. Patton Founder, Chief Scientific Officer and Director 190.8K 76.5K — 28.0K — 6.1K 273.4K 10.24% ↗
196 1999 Stephen L. Hurst Vice President, Human Resources 179.3K 57.6K — 21.6K — 1.2K 238.1K 9.07% ↗
197 1999 Brigid A. Makes Vice President, Finance Administration, Chief Financial Officer and Assistant Secretary 87.7K 30.0K — 140.0K — 175.00 117.9K 118.73% ↗
198 1999 Douglas H. Altschuler Vice President, General Counsel and Secretary — — — — — — — — ↗
CEO compensation breakdown

Proxy statements

Proxy statements (DEF 14A)
Filing date Form type Filing
2026-04-24 DEFA14A ↗
2026-04-24 DEF 14A ↗
2025-04-25 DEF 14A ↗
2025-04-15 PRE 14A ↗

Recent SEC filings

Recent SEC filings
Filing date Form type Filing
2026-05-07 8-K ↗
2026-05-06 SC 13G/A ↗
2026-04-24 DEFA14A ↗
2026-04-24 DEF 14A ↗
2026-04-24 ARS ↗
2026-04-23 8-K ↗
2026-04-23 424B5 ↗
2026-04-20 8-K ↗
2026-04-20 8-K ↗
2026-04-20 424B5 ↗

Executive team

NameTitleCompensationGender
Howard W. Robin Chief Executive Officer, President & Director 2M male
Jonathan Zalevsky Senior Vice President and Chief Research & Development Officer 1M —
Sandra A. Gardiner Interim Chief Financial Officer 686.4K female
Jennifer Ruddock Chief Business Officer — female
Ken Franke Senior Vice President of Biologics Process Development & Manufacturing — —
Mary Tagliaferri Chief Medical Officer — —
Robert Bacci Chief People Officer and Head of Quality & Facilities — male
Charleen Jue Senior Vice President of Clinical Development Operations — female
Takahiro Miyazaki Senior VP & Head of Research — male
Elizabeth Zhang VP of Legal, Corporate Counsel & Secretary — female
Jason Barnard Chief Accounting Officer — male
ESG Rating
C+
BIOTECHNOLOGY
2013
E (Environmental)
50.8 / 56.3
Company / Sector avg.
S (Social)
68.6 / 62.4
Company / Sector avg.
G (Governance)
59.2 / 60.9
Company / Sector avg.
ESG Total
59.5 / 59.9
Company / Sector avg.
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Biotechnology